Kistler Tiffany Companies, LLC Blueprint Medicines Corp Transaction History
Kistler Tiffany Companies, LLC
- $615 Million
- Q2 2023
A detailed history of Kistler Tiffany Companies, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Kistler Tiffany Companies, LLC holds 100 shares of BPMC stock, worth $10,903. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$10,903
Previous $4,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BPMC
# of Institutions
313Shares Held
60.6MCall Options Held
634KPut Options Held
691K-
Black Rock Inc. New York, NY6.45MShares$703 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.31MShares$688 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.25MShares$682 Million0.07% of portfolio
-
Wellington Management Group LLP Boston, MA4.18MShares$455 Million0.07% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.5MShares$272 Million6.2% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $6.51B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...